Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Over the last 12 months, insiders at Avenue Therapeutics, Inc. have bought $1,250 and sold $86,697 worth of Avenue Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Avenue Therapeutics, Inc. have bought $178,900 and sold $786,189 worth of stock each year.
Highest buying activity among insiders over the last 12 months: KRANZLER JAY D (director) — $1,250.
The last purchase of 497 shares for transaction amount of $1,243 was made by KRANZLER JAY D (director) on 2024‑09‑30.
2024-11-05 | Sale | director | 61 0.0043% | $2.24 | $137 | +1.12% | ||
2024-09-30 | director | 497 0.037% | $2.50 | $1,243 | -16.47% | |||
2024-09-27 | director | 3 0.0002% | $2.40 | $7 | -16.93% | |||
2023-12-11 | Sale | 10 percent owner | 617,000 4.9094% | $0.14 | $86,560 | -59.90% | ||
2023-09-08 | 10 percent owner | 418,410 4.9086% | $0.72 | $301,255 | -80.21% | |||
2023-09-08 | director | 348,675 4.0905% | $0.72 | $251,046 | -80.21% | |||
2022-10-11 | Sale | director | 388,888 48.3396% | $7.71 | $3M | -59.86% | ||
2021-09-15 | Sale | Chief Financial Officer | 7,160 0.042% | $1.62 | $11,599 | -69.16% | ||
2021-05-06 | director | 2,500 0.0142% | $3.99 | $9,975 | -68.56% | |||
2020-08-20 | Sale | Chief Financial Officer | 3,840 0.0235% | $12.13 | $46,579 | -60.88% | ||
2020-03-10 | Chief Financial Officer | 1,889 0.0115% | $7.94 | $14,999 | +12.63% | |||
2020-03-09 | Chief Financial Officer | 1,500 0.0093% | $7.99 | $11,983 | +13.49% | |||
2020-02-27 | director | 2,400 0.0139% | $8.20 | $19,680 | +3.72% | |||
2020-02-26 | director | 161 0.001% | $8.73 | $1,406 | +0.45% | |||
2020-02-25 | director | 10,000 0.0629% | $9.31 | $93,100 | -0.89% | |||
2020-02-25 | Chief Financial Officer | 1,200 0.0074% | $9.09 | $10,908 | -0.89% | |||
2019-09-12 | director | 16,000 0.0982% | $6.27 | $100,320 | +46.39% | |||
2019-08-09 | Sale | Chief Financial Officer | 2,375 0.0138% | $5.56 | $13,205 | +49.32% | ||
2019-08-08 | Sale | Chief Financial Officer | 2,313 0.0141% | $5.62 | $12,999 | +55.35% | ||
2019-06-18 | director | 2,000 0.0126% | $5.83 | $11,660 | +21.09% |